ArticleJournal of orthopaedic surgery and research2025
Kruppel-like factor 9 may regulate the inflammatory injury of chondrocytes by affecting NF-κB signaling.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of diagnostic and prognostic hub genes in osteoarthritis: an integrated bioinformatics study.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKruppel-like factor 9 (KLF9) is involved in the development of osteoarthritis (OA), which is a chronic joint disorder. However, the pathogenesis of OA remains unclear. This study aimed to investigate the relationship between KLF9 and the pathogenesis of OA.
methodsKLF9 expression in the Gene Expression Omnibus database was analyzed, and the most significantly upregulated and downregulated genes were visualized using a volcano map. Analyses were performed using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes to determine the most significantly changed genes. Interleukin-1 beta (IL-1β) was applied to CHON-001 cells and human synovial cells (HSyCs) to establish an OA in vitro cell model. Real-time quantitative polymerase chain reaction (RT-qPCR) and western blot analysis were conducted to evaluate the expressions of KLF9 and cell death genes. Enzyme-linked immunosorbent assay (ELISA) was conducted to examine IL-1β, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). IL-1β induced CHON-001 cells; HSyCs were transfected with KLF9 overexpression (OE); and ELISA was conducted to examine IL-1β, IL-6, and TNF-α. An inhibitor of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was used, and its effects on CHON-001 cells and HSyC were examined.
resultsKLF9 was one of the most significantly downregulated genes during OA development. KLF9 was downregulated in IL-1β-treated CHON-001 cells and HSyCs. IL-1β induced the significant upregulation of IL-1β, IL-6, and TNF-α and increased cell death in CHON-001 cells and HSyCs. KLF9 OE partially mitigated the effects of IL-1β and markedly attenuated the IL-1β-induced upregulation of TNF-α and IL-6. IL-1β treatment significantly upregulated B-cell lymphoma 2-associated X protein (Bax) and Caspase-3 and downregulated B-cell lymphoma 2 (Bcl-2) on both messenger ribonucleic acid and protein levels, and KLF9 OE mitigated the effects of IL-1β. IL-1β decreased the levels of type II collagen and aggrecan, whereas KLF9 OE increased the levels of type II collagen and aggrecan. An NF-κB inhibitor could partially abrogate the KLF9-induced effects on Bax, Caspase-3, and Bcl-2. The NF-κB inhibitor also reversed the KLF9 OE-induced increase in the levels of type II collagen and aggrecan.
conclusionsKLF9 mitigated the IL-1β-induced inflammatory condition via the NF-κB pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.